Dipraglurant (Immediate Release), for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID).
We are developing dipraglurant as a novel orally available mGlu5 NAM for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID). This is a disease with significant commercial opportunity as improved therapies are needed.
We believe that, subject to regulatory approval, dipraglurant may offer an innovative and differentiated treatment approach from existing therapies.
In a 28 day Phase 2a placebo-controlled clinical trial, conducted in the United States and Europe, in patients with PD-LID, dipraglurant met its primary end point, was generally well tolerated and no clinically significant abnormalities of safety monitoring parameters occurred. In addition, at Day 1 and Day 14, dipraglurant showed statistically significant effects on PD-LID clinical symptoms, as measured using the modified abnormal involuntary movement scale, or mAIMs. However, an increasing placebo response resulted in the effect of dipraglurant on PD-LID clinical symptoms not showing statistical significance at Day 28.
We have received orphan drug designation from the FDA, for dipraglurant in PD-LID.